Date Filed | Type | Description |
02/05/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
01/27/2021 |
SC 13G/A
| Centerbridge Credit Partners, L.P. reports a 0% stake in American Renal Associates Holdings, Inc. |
01/27/2021 |
4
| CENTERBRIDGE CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed of 16,893,850 shares
@ $0 Disposed of 523,697 shares
@ $0 Disposed of 198,289 shares
@ $0 |
|
01/26/2021 |
4
| ERICKSON THOMAS W (Director) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 49,435 shares
@ $0 Disposed/sold 18,320 shares
@ $0 |
|
01/26/2021 |
4
| Hocevar Christopher J (Director) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 18,679 shares
@ $0 |
|
01/26/2021 |
4
| Carlucci Joseph A (CEO) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 590,879 shares
@ $0 Disposed/sold 654,285 shares
@ $0 Disposed/sold 199,307 options to buy
@ $6.47, valued at
$1.3M
|
|
01/26/2021 |
4
| Jureller John M (Director) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 49,435 shares
@ $0 |
|
01/26/2021 |
4
| Kamal Syed T (President) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 1,291,236 shares
@ $0 Disposed/sold 199,307 options to buy
@ $6.47, valued at
$1.3M
|
|
01/26/2021 |
4
| Labriola Victoria (VP and General Counsel) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 64,569 shares
@ $0 Disposed/sold 15,949 options to buy
@ $6.27, valued at
$100k
Disposed/sold 9,139 options to buy
@ $10.19, valued at
$93.1k
|
|
01/26/2021 |
4
| FISH ROBERT H (Director) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 43,205 shares
@ $0 |
|
01/26/2021 |
4
| Williamson Don E (EVP, COO) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 307,282 shares
@ $0 Disposed/sold 11,970 options to buy
@ $1.28, valued at
$15.3k
Disposed/sold 5,725 options to buy
@ $6.47, valued at
$37k
|
|
01/26/2021 |
4
| BOXER MICHAEL (Director) has filed a Form 4 on American Renal Associates Holdings, Inc.
Txns:
| Disposed/sold 13,801 shares
@ $0 Disposed/sold 53,954 shares
@ $0 Disposed/sold 32,713 shares
@ $0 |
|
01/26/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
01/26/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
01/26/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
01/26/2021 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs:
|
"Fourth Amended and Restated Certificate of Incorporation of American Renal Associates Holdings, Inc",
"Second Amended and Restated Bylaws of American Renal Associates Holdings, Inc",
"BEVERLY, Mass. — Nautic Partners and its portfolio company, Innovative Renal Care , have completed the previously announced transaction to acquire American Renal Associates Holdings, Inc. , effective January 25, 2021. The transaction creates a unique opportunity to shape the future of kidney care during a dynamic time of change, innovation and transformation in the industry. “As the healthcare industry continues to evolve, recent innovation throughout kidney and renal care has allowed for dramatic and exciting improvements in care delivery and patient experience,” said Nick Mendez, president and CEO of IRC. “ARA’s significant infrastructure and geographic footprint provides a unique opportunity to advance the development of a comprehensive renal care model for the patients and communities ..." |
|
01/14/2021 |
8-K
| Quarterly results |
01/06/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
12/15/2020 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
11/24/2020 |
PREM14A
| Form PREM14A - Preliminary proxy statements relating to merger or acquisition: |
11/05/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
10/09/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/02/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/02/2020 |
8-K/A
| Quarterly results |
10/02/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/02/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/02/2020 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/02/2020 |
8-K
| Quarterly results |
09/21/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/18/2020 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
08/10/2020 |
8-K
| Quarterly results |
08/10/2020 |
10-Q
| Quarterly Report for the period ended June 30, 2020 |
07/09/2020 |
8-K
| Quarterly results |
07/09/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|